Literature DB >> 11262460

Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization.

R L Davis1, M B Hasselquist, V Cardenas, D M Zerr, J Kramer, A Zavitkovsky, A Schuchat.   

Abstract

OBJECTIVE: Our purpose was to assess the impact of new consensus guidelines issued by the Centers for Disease Control and Prevention, The American College of Obstetricians and Gynecologists, and the American Academy of Pediatrics to prevent perinatal group B streptococcal disease. STUDY
DESIGN: We performed a descriptive analysis and a before-and-after analysis of implementation of the group B streptococcal disease prevention guidelines among singleton-birth pregnancies in 2 Group Health Cooperative hospitals from October 1, 1995, through December 31, 1997. We studied the speed and completeness of implementation and the effect on pregnancy care practices including intrapartum antibiotic use, test ordering, and maternal and neonatal health.
RESULTS: Guideline implementation occurred rapidly. The proportion of term pregnancies screened according to the guideline increased markedly, and overall intrapartum antibiotic use more than doubled. Among group B streptococci-positive women, intrapartum antibiotic prophylaxis increased from 24% before to 74% after guideline implementation. Median duration of treatment before delivery increased from 1.8 to 4.3 hours. The rate of rash did not increase, and there were no cases of anaphylaxis or pseudomembranous colitis. The proportion of infants undergoing evaluation decreased after implementation of the neonatal guidelines; among infants of group B streptococci-negative women, test ordering dropped by almost 40%.
CONCLUSIONS: Implementation of the new guidelines is feasible and can be accomplished rapidly. The guidelines were associated with increased maternal intrapartum antibiotic use, particularly among women at highest risk, and with a decrease in laboratory use for infants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262460     DOI: 10.1067/mob.2001.110308

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Interpretation of 2002 Centers for Disease Control guidelines for group B streptococcus and evolving provider practice patterns.

Authors:  Emma L Barber; Edmund F Funai; Michael B Bracken; Jessica L Illuzzi
Journal:  Am J Perinatol       Date:  2010-07-16       Impact factor: 1.862

2.  Preventing group B streptococcal infections: new recommendations.

Authors:  H Dele Davies
Journal:  Can J Infect Dis       Date:  2002-07

3.  Preventing group B streptococcal infections: New recommendations.

Authors:  H Dele Davies
Journal:  Paediatr Child Health       Date:  2002-07       Impact factor: 2.253

4.  Evaluation of StrepBSelect Chromogenic Medium and the Fast-Track Diagnostics Group B Streptococcus (GBS) Real-Time PCR Assay Compared to Routine Culture for Detection of GBS during Antepartum Screening.

Authors:  Deirdre L Church; Heather Baxter; Tracie Lloyd; Oscar Larios; Daniel B Gregson
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

5.  Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery.

Authors:  Emma L Barber; Guomao Zhao; Irina A Buhimschi; Jessica L Illuzzi
Journal:  Obstet Gynecol       Date:  2008-08       Impact factor: 7.661

6.  Group B Streptococcus colonization induces Prevotella and Megasphaera abundance-featured vaginal microbiome compositional change in non-pregnant women.

Authors:  Xiaofeng Mu; Changying Zhao; Junjie Yang; Xiaofang Wei; Jiaming Zhang; Cheng Liang; Zhongtao Gai; Chunling Zhang; Dequan Zhu; Ye Wang; Lei Zhang
Journal:  PeerJ       Date:  2019-08-16       Impact factor: 2.984

7.  Cost-effectiveness of universal prophylaxis in pregnancy with prior group B streptococci colonization.

Authors:  Mark A Turrentine; Mildred M Ramirez; Joan M Mastrobattista
Journal:  Infect Dis Obstet Gynecol       Date:  2009-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.